Stereotaxis, Inc. (STXS)
NYSEAMERICAN: STXS · Real-Time Price · USD
2.700
+0.040 (1.50%)
At close: Aug 13, 2025, 4:00 PM
2.720
+0.020 (0.74%)
Pre-market: Aug 14, 2025, 9:27 AM EDT
Stereotaxis Revenue
Stereotaxis had revenue of $8.80M in the quarter ending June 30, 2025, with 95.42% growth. This brings the company's revenue in the last twelve months to $31.81M, up 33.94% year-over-year. In the year 2024, Stereotaxis had annual revenue of $26.92M with 0.55% growth.
Revenue (ttm)
$31.81M
Revenue Growth
+33.94%
P/S Ratio
7.39
Revenue / Employee
$228,820
Employees
139
Market Cap
249.07M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 26.92M | 147.00K | 0.55% |
Dec 31, 2023 | 26.77M | -1.38M | -4.89% |
Dec 31, 2022 | 28.15M | -6.87M | -19.63% |
Dec 31, 2021 | 35.02M | 8.39M | 31.51% |
Dec 31, 2020 | 26.63M | -2.27M | -7.86% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
STXS News
- 5 days ago - Stereotaxis, Inc. (STXS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Stereotaxis Reports 2025 Second Quarter Financial Results - GlobeNewsWire
- 17 days ago - Stereotaxis Receives U.S. FDA Clearance for MAGiC Sweep Catheter - GlobeNewsWire
- 22 days ago - Stereotaxis to Report Second Quarter 2025 Financial Results on August 7, 2025 - GlobeNewsWire
- 4 weeks ago - Stereotaxis Announces $12.5 Million Registered Direct Offering of Common Stock - GlobeNewsWire
- 5 weeks ago - Stereotaxis: Recurring Revenue Inflection - Seeking Alpha
- 6 weeks ago - First Clinical Results from MAGiC Catheter Study Published in the Journal of Interventional Cardiac Electrophysiology - GlobeNewsWire
- 3 months ago - Stereotaxis, Inc. (STXS) Q1 2025 Earnings Call Transcript - Seeking Alpha